Evonik Industries will eliminate 90 jobs by closing its Hamburg and Bitterfeld plants in 2027 – 50 positions in Hamburg’s cosmetics‑and‑care unit and 40 in Bitterfeld’s chlorosilane operation, according to a Handelsblatt report published on 11 September 2026.
Job cuts and plant closures
The Hamburg site currently employs 50 people in cosmetics‑and‑care production, while the Bitterfeld location employs 40 people producing chlorosilanes. Both facilities are slated for shutdown in the next calendar year, with the company promising “sozialverträgliche Lösungen” – socially responsible arrangements – in close coordination with employee representatives.
| Site | Location | Jobs Affected | Product Focus | Closure Year |
|---|---|---|---|---|
| Hamburg | Hamburg, Germany | 50 | Cosmetics & Care | 2027 |
| Bitterfeld | Bitterfeld, Germany | 40 | Chlorosilanes | 2027 |
| Source: Handelsblatt | ||||
Why Evonik is consolidating
Interim CEO Claus Rettig told Handelsblatt that production, administrative and laboratory structures are “zu stark fragmentiert” – too fragmented – which drives “unnötig hohen Kosten” and weakens competitiveness. By concentrating activities at larger sites, Evonik aims to lower costs, speed up innovation and strengthen its market position.
The closures are part of a broader effort to reduce fragmented structures and improve cost competitiveness, a theme echoed throughout the company’s recent communications. The move follows a larger workforce reduction earlier in 2026 that saw more than 2,000 jobs cut across the group.
Sector‑wide implications
Germany’s specialty chemicals industry has been undergoing a wave of consolidations as firms grapple with rising input costs, stricter environmental regulations and a competitive global market. Evonik’s 90‑job reduction adds to a series of recent restructurings, including BASF’s plant rationalisations and Lanxess’s site closures.
While the absolute number of jobs cut is modest compared with the sector’s total employment of roughly 350,000, the strategic signal is significant. Concentrating production in larger, more efficient sites can improve margins, but it also raises questions about regional employment stability and the capacity of local labour markets to absorb displaced workers.
Investors typically watch such moves for clues about future earnings guidance. Consolidation can lead to lower operating expenses, which may support Evonik’s profitability targets for the 2027‑2029 period. However, the short‑term integration costs and any severance or transition expenses are not disclosed, leaving a gap in the financial picture.
Outlook and unanswered questions
- What specific larger sites will absorb the Hamburg and Bitterfeld production lines? The announcement does not name the receiving facilities.
- How will the transition affect Evonik’s supply chain, particularly for downstream customers reliant on the chlorosilane and cosmetics‑care product streams?
- Will the socially responsible solutions for the 90 affected employees include redeployment within Evonik’s German footprint, or will external job placement be necessary?
- How does the cost‑saving potential compare with the capital expenditures required to upgrade the receiving sites?
Until Evonik releases a detailed integration plan, analysts will have to monitor the company’s quarterly reports for any revisions to operating expense forecasts or capital‑expenditure guidance.
For readers tracking German industrial restructuring, the closures underscore a trend toward fewer, larger, more cost‑efficient plants. The sector’s employment landscape will likely continue to shift, with regional impacts depending on how quickly displaced workers can be re‑skilled or relocated.